{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:51:43Z","timestamp":1781830303256,"version":"3.54.5"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82260555"],"award-info":[{"award-number":["82260555"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Major Science and Technology Projects of Gansu Province","award":["22ZD6FA021-4"],"award-info":[{"award-number":["22ZD6FA021-4"]}]},{"name":"Joint Research Fund General Projects of Gansu Province","award":["23JRRA1508"],"award-info":[{"award-number":["23JRRA1508"]}]},{"name":"Gansu Provincial Top-notch Talent Program","award":["(2023)9"],"award-info":[{"award-number":["(2023)9"]}]},{"name":"Cuiying Science and Technology Innovation Project of the Second Hospital of Lanzhou University","award":["CY2024-CQ-01"],"award-info":[{"award-number":["CY2024-CQ-01"]}]},{"name":"Public Hospital High-quality Development of Scientific Research Project of Chinese Health Promotion Foundation","award":["GL-C032"],"award-info":[{"award-number":["GL-C032"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hum Genomics"],"DOI":"10.1186\/s40246-026-00970-7","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T09:04:27Z","timestamp":1778490267000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SLC26A2 as a key regulator and therapeutic target in hepatocellular carcinoma: evidence from pan-cancer and mechanistic studies"],"prefix":"10.1186","volume":"20","author":[{"given":"Rui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xijie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wence","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"970_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"970_CR2","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3350\/cmh.2023.0070","volume":"29","author":"JH Oh","year":"2023","unstructured":"Oh JH, Jun DW. The latest global burden of liver cancer: a past and present threat. Clin Mol Hepatol. 2023;29:355\u20137. https:\/\/doi.org\/10.3350\/cmh.2023.0070.","journal-title":"Clin Mol Hepatol"},{"key":"970_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/978-3-030-65768-0_9","volume":"1311","author":"J Salazar","year":"2021","unstructured":"Salazar J, Le A. The heterogeneity of liver cancer metabolism. Adv Exp Med Biol. 2021;1311:127\u201336. https:\/\/doi.org\/10.1007\/978-3-030-65768-0_9.","journal-title":"Adv Exp Med Biol"},{"key":"970_CR4","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ccell.2024.01.007","volume":"42","author":"X Yang","year":"2024","unstructured":"Yang X, Yang C, Zhang S, Geng H, Zhu AX, Bernards R, et al. Precision treatment in advanced hepatocellular carcinoma. Cancer Cell. 2024;42:180\u201397. https:\/\/doi.org\/10.1016\/j.ccell.2024.01.007.","journal-title":"Cancer Cell"},{"key":"970_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s43556-024-00184-0","volume":"5","author":"Y Xue","year":"2024","unstructured":"Xue Y, Ruan Y, Wang Y, Xiao P, Xu J. Signaling pathways in liver cancer: pathogenesis and targeted therapy. Mol Biomed. 2024;5:20. https:\/\/doi.org\/10.1186\/s43556-024-00184-0.","journal-title":"Mol Biomed"},{"key":"970_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01535-8","volume":"17","author":"Q Lu","year":"2024","unstructured":"Lu Q, Kou D, Lou S, Ashrafizadeh M, Aref AR, Canadas I, et al. Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy. J Hematol Oncol. 2024;17:16. https:\/\/doi.org\/10.1186\/s13045-024-01535-8.","journal-title":"J Hematol Oncol"},{"key":"970_CR7","first-page":"3106","volume":"10","author":"W Lin","year":"2020","unstructured":"Lin W, Wang C, Liu G, Bi C, Wang X, Zhou Q, et al. LncRNAs regulate metabolism in cancer. Am J Cancer Res. 2020;10:3106\u201326.","journal-title":"Am J Cancer Res"},{"key":"970_CR8","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.3892\/or.2017.5840","volume":"38","author":"S Wei","year":"2017","unstructured":"Wei S, Fan Q, Yang L, Zhang X, Ma Y, Zong Z, et al. Promotion of glycolysis by HOTAIR through GLUT1 upregulation via mTOR signaling. Oncol Rep. 2017;38:1902\u20138. https:\/\/doi.org\/10.3892\/or.2017.5840.","journal-title":"Oncol Rep"},{"key":"970_CR9","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1097\/HEP.0000000000000314","volume":"78","author":"L Cheng","year":"2023","unstructured":"Cheng L, Deepak R, Wang G, Meng Z, Tao L, Xie M, et al. Hepatic mitochondrial NAD+ transporter SLC25A47 activates AMPK\u03b1 mediating lipid metabolism and tumorigenesis. Hepatology. 2023;78:1828\u201342. https:\/\/doi.org\/10.1097\/HEP.0000000000000314.","journal-title":"Hepatology"},{"key":"970_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115198","volume":"203","author":"Y Huang","year":"2022","unstructured":"Huang Y, Xian L, Liu Z, Wei L, Qin L, Xiong Y, et al. AMPK\u03b12\/HNF4A\/BORIS\/GLUT4 pathway promotes hepatocellular carcinoma cell invasion and metastasis in low glucose microenviroment. Biochem Pharmacol. 2022;203:115198. https:\/\/doi.org\/10.1016\/j.bcp.2022.115198.","journal-title":"Biochem Pharmacol"},{"key":"970_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.freeradbiomed.2022.02.014","volume":"182","author":"L Bai","year":"2022","unstructured":"Bai L, Yang ZX, Ma PF, Liu JS, Wang DS, Yu HC. Overexpression of SLC25A51 promotes hepatocellular carcinoma progression by driving aerobic glycolysis through activation of SIRT5. Free Radic Biol Med. 2022;182:11\u201322. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2022.02.014.","journal-title":"Free Radic Biol Med"},{"key":"970_CR12","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1002\/hep4.2031","volume":"6","author":"D Wang","year":"2022","unstructured":"Wang D, Wu H, Yang J, Li M, Ling C, Gao Z, et al. Loss of SLC46A1 decreases tumor iron content in hepatocellular carcinoma. Hepatol Commun. 2022;6:2914\u201324. https:\/\/doi.org\/10.1002\/hep4.2031.","journal-title":"Hepatol Commun"},{"key":"970_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0909-7","volume":"17","author":"H Wang","year":"2018","unstructured":"Wang H, Chen W, Jin M, Hou L, Chen X, Zhang R, et al. CircSLC3A2 functions as an oncogenic factor in hepatocellular carcinoma by sponging miR-490-3p and regulating PPM1F expression. Mol Cancer. 2018;17:165. https:\/\/doi.org\/10.1186\/s12943-018-0909-7.","journal-title":"Mol Cancer"},{"key":"970_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1177-0","volume":"38","author":"W Li","year":"2019","unstructured":"Li W, Dong X, He C, Tan G, Li Z, Zhai B, et al. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells. J Exp Clin Cancer Res. 2019;38:183. https:\/\/doi.org\/10.1186\/s13046-019-1177-0.","journal-title":"J Exp Clin Cancer Res"},{"key":"970_CR15","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1007\/s10620-023-07824-5","volume":"68","author":"H Li","year":"2023","unstructured":"Li H, Lan H, Zhang M, Zhao F, An N, Yi C. TEA domain transcription factor 1 inhibits ferroptosis and sorafenib sensitivity of hepatocellular carcinoma cells. Dig Dis Sci. 2023;68:3070\u201382. https:\/\/doi.org\/10.1007\/s10620-023-07824-5.","journal-title":"Dig Dis Sci"},{"key":"970_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03853-y","volume":"12","author":"S Xia","year":"2021","unstructured":"Xia S, Wu J, Zhou W, Zhang M, Zhao K, Liu J, et al. SLC7A2 deficiency promotes hepatocellular carcinoma progression by enhancing recruitment of myeloid-derived suppressors cells. Cell Death Dis. 2021;12:570. https:\/\/doi.org\/10.1038\/s41419-021-03853-y.","journal-title":"Cell Death Dis"},{"key":"970_CR17","doi-asserted-by":"publisher","first-page":"53571","DOI":"10.18632\/oncotarget.10670","volume":"7","author":"F Teng","year":"2016","unstructured":"Teng F, Guo M, Liu F, Wang C, Dong J, Zhang L, et al. Treatment with an SLC12A1 antagonist inhibits tumorigenesis in a subset of hepatocellular carcinomas. Oncotarget. 2016;7:53571\u201382. https:\/\/doi.org\/10.18632\/oncotarget.10670.","journal-title":"Oncotarget"},{"key":"970_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2020.07.001","volume":"45","author":"J Tian","year":"2021","unstructured":"Tian J, Hu D. LncRNA SLC16A1-AS1 is upregulated in hepatocellular carcinoma and predicts poor survival. Clin Res Hepatol Gastroenterol. 2021;45:101490. https:\/\/doi.org\/10.1016\/j.clinre.2020.07.001.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"970_CR19","doi-asserted-by":"publisher","first-page":"34617","DOI":"10.18632\/oncotarget.16119","volume":"8","author":"E Herraez","year":"2017","unstructured":"Herraez E, Sanchez-Vicente L, Macias RIR, Briz O, Marin JJG. Usefulness of the MRP2 promoter to overcome the chemoresistance of gastrointestinal and liver tumors by enhancing the expression of the drug transporter OATP1B1. Oncotarget. 2017;8:34617\u201329. https:\/\/doi.org\/10.18632\/oncotarget.16119.","journal-title":"Oncotarget"},{"key":"970_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48028-3","volume":"15","author":"W Hu","year":"2024","unstructured":"Hu W, Song A, Zheng H. Substrate binding plasticity revealed by Cryo-EM structures of SLC26A2. Nat Commun. 2024;15:3616. https:\/\/doi.org\/10.1038\/s41467-024-48028-3.","journal-title":"Nat Commun"},{"key":"970_CR21","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.ebiom.2019.01.010","volume":"40","author":"C Zheng","year":"2019","unstructured":"Zheng C, Lin X, Xu X, Wang C, Zhou J, Gao B, et al. Suppressing UPR-dependent overactivation of FGFR3 signaling ameliorates SLC26A2-deficient chondrodysplasias. EBioMedicine. 2019;40:695\u2013709. https:\/\/doi.org\/10.1016\/j.ebiom.2019.01.010.","journal-title":"EBioMedicine"},{"key":"970_CR22","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1158\/1541-7786.MCR-16-0234","volume":"15","author":"LY Dimberg","year":"2017","unstructured":"Dimberg LY, Towers CG, Behbakht K, Hotz TJ, Kim J, Fosmire S, et al. A genome-wide loss-of-function screen identifies SLC26A2 as a novel mediator of TRAIL resistance. Mol Cancer Res. 2017;15:382\u201394. https:\/\/doi.org\/10.1158\/1541-7786.MCR-16-0234.","journal-title":"Mol Cancer Res"},{"key":"970_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cells9020397","author":"HC Huang","year":"2020","unstructured":"Huang HC, Cai BH, Suen CS, Lee HY, Hwang MJ, Liu FT, et al. BGN\/TLR4\/NF-\u03baB mediates epigenetic silencing of immunosuppressive Siglec ligands in colon cancer cells. Cells. 2020. https:\/\/doi.org\/10.3390\/cells9020397.","journal-title":"Cells"},{"key":"970_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08422-2","volume":"21","author":"Y Shi","year":"2021","unstructured":"Shi Y, Yang D, Qin Y. Identifying prognostic lncRNAs based on a ceRNA regulatory network in laryngeal squamous cell carcinoma. BMC Cancer. 2021;21:705. https:\/\/doi.org\/10.1186\/s12885-021-08422-2.","journal-title":"BMC Cancer"},{"key":"970_CR25","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48:W509\u201314. https:\/\/doi.org\/10.1093\/nar\/gkaa407.","journal-title":"Nucleic Acids Res"},{"key":"970_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkt1248","volume":"42","author":"JH Li","year":"2014","unstructured":"Li JH, Liu S, Zhou H, Qu LH, Yang JH. StarBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein\u2013RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42:D92-97. https:\/\/doi.org\/10.1093\/nar\/gkt1248.","journal-title":"Nucleic Acids Res"},{"key":"970_CR27","doi-asserted-by":"publisher","first-page":"5931","DOI":"10.7150\/thno.110567","volume":"15","author":"B Pan","year":"2025","unstructured":"Pan B, Chen S, Wu H, Zhang X, Zhang Z, Ye D, et al. Short-term starvation inhibits CD36 N-glycosylation and downregulates USP7 UFMylation to alleviate RBPJ-maintained T cell exhaustion in liver cancer. Theranostics. 2025;15:5931\u201352. https:\/\/doi.org\/10.7150\/thno.110567.","journal-title":"Theranostics"},{"key":"970_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011716","author":"Y Tang","year":"2025","unstructured":"Tang Y, Yang J, Shen Q, Gao Z, Wu M, Wu C, et al. Targeting annexin A2 to reactivate tumor-associated antigens presentation and relieve immune tolerance in liver cancer. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2025-011716.","journal-title":"J Immunother Cancer"},{"key":"970_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-08305-5","volume":"17","author":"B Pan","year":"2025","unstructured":"Pan B, Yu H, Lin Z, Liu M, Liu J, Xu Y, et al. RNASEH2C enhances TRAF3IP1 to degrade RAI14 in lysosomes thus hindering macrophage antigen presentation and advancing liver cancer. Cell Death Dis. 2025;17:92. https:\/\/doi.org\/10.1038\/s41419-025-08305-5.","journal-title":"Cell Death Dis"},{"key":"970_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-025-03622-1","volume":"45","author":"T Yang","year":"2026","unstructured":"Yang T, Han Y, Wang Y, Li R, Zhang X, Zhang X, et al. Psammaplysene D overcomes sorafenib resistance in liver cancer by targeting FGFR4\/CYP26A1-retinoic acid axis to drive ferroptosis. J Exp Clin Cancer Res. 2026;45:44. https:\/\/doi.org\/10.1186\/s13046-025-03622-1.","journal-title":"J Exp Clin Cancer Res"},{"key":"970_CR31","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/hmg\/ddi079","volume":"14","author":"A Forlino","year":"2005","unstructured":"Forlino A, Piazza R, Tiveron C, Della Torre S, Tatangelo L, Bonafe L, et al. A diastrophic dysplasia sulfate transporter (SLC26A2) mutant mouse: morphological and biochemical characterization of the resulting chondrodysplasia phenotype. Hum Mol Genet. 2005;14:859\u201371. https:\/\/doi.org\/10.1093\/hmg\/ddi079.","journal-title":"Hum Mol Genet"},{"key":"970_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ajmg.a.31483","volume":"143A","author":"A Superti-Furga","year":"2007","unstructured":"Superti-Furga A, Unger S. Nosology and classification of genetic skeletal disorders: 2006 revision. Am J Med Genet A. 2007;143A:1\u201318. https:\/\/doi.org\/10.1002\/ajmg.a.31483.","journal-title":"Am J Med Genet A"},{"key":"970_CR33","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/0092-8674(94)90281-x","volume":"78","author":"J Hastbacka","year":"1994","unstructured":"Hastbacka J, de la Chapelle A, Mahtani MM, Clines G, Reeve-Daly MP, Daly M, Hamilton BA, Kusumi K, Trivedi B, Weaver A. The diastrophic dysplasia gene encodes a novel sulfate transporter: positional cloning by fine-structure linkage disequilibrium mapping. Cell. 1994;78:1073\u201387. https:\/\/doi.org\/10.1016\/0092-8674(94)90281-x.","journal-title":"Cell"},{"key":"970_CR34","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1007\/s00424-003-1090-3","volume":"447","author":"DB Mount","year":"2004","unstructured":"Mount DB, Romero MF. The SLC26 gene family of multifunctional anion exchangers. Pflugers Arch. 2004;447:710\u201321. https:\/\/doi.org\/10.1007\/s00424-003-1090-3.","journal-title":"Pflugers Arch"},{"key":"970_CR35","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.tcb.2021.08.002","volume":"32","author":"R Chen","year":"2022","unstructured":"Chen R, Chen L. Solute carrier transporters: emerging central players in tumour immunotherapy. Trends Cell Biol. 2022;32:186\u2013201. https:\/\/doi.org\/10.1016\/j.tcb.2021.08.002.","journal-title":"Trends Cell Biol"},{"key":"970_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00645-2","volume":"12","author":"LL Sun","year":"2024","unstructured":"Sun LL, He HY, Li W, Jin WL, Wei YJ. The solute carrier transporters (SLCs) family in nutrient metabolism and ferroptosis. Biomark Res. 2024;12:94. https:\/\/doi.org\/10.1186\/s40364-024-00645-2.","journal-title":"Biomark Res"},{"key":"970_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.70343","volume":"8","author":"MS Hossen","year":"2025","unstructured":"Hossen MS, Islam MSU, Yasin M, Ibrahim M, Das A. A review on the role of human solute carriers transporters in cancer. Health Sci Rep. 2025;8:e70343. https:\/\/doi.org\/10.1002\/hsr2.70343.","journal-title":"Health Sci Rep"},{"key":"970_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2024.101952","volume":"84","author":"K Hushmandi","year":"2024","unstructured":"Hushmandi K, Einollahi B, Saadat SH, Lee EHC, Farani MR, Okina E, et al. Amino acid transporters within the solute carrier superfamily: underappreciated proteins and novel opportunities for cancer therapy. Mol Metab. 2024;84:101952. https:\/\/doi.org\/10.1016\/j.molmet.2024.101952.","journal-title":"Mol Metab"},{"key":"970_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jmcb\/mjy052","volume":"11","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Zhang Y, Sun K, Meng Z, Chen L. The SLC transporter in nutrient and metabolic sensing, regulation, and drug development. J Mol Cell Biol. 2019;11:1\u201313. https:\/\/doi.org\/10.1093\/jmcb\/mjy052.","journal-title":"J Mol Cell Biol"},{"key":"970_CR40","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060\u201372. https:\/\/doi.org\/10.1016\/j.cell.2012.03.042.","journal-title":"Cell"},{"key":"970_CR41","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","volume":"12","author":"P Koppula","year":"2021","unstructured":"Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2021;12:599\u2013620. https:\/\/doi.org\/10.1007\/s13238-020-00789-5.","journal-title":"Protein Cell"},{"key":"970_CR42","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/HEP.0000000000000783","volume":"81","author":"B He","year":"2025","unstructured":"He B, Huang Z, Qin S, Peng P, Duan X, Wang L, et al. Enhanced SLC35B2\/SAV1 sulfation axis promotes tumor growth by inhibiting Hippo signaling in HCC. Hepatology. 2025;81:436\u201352. https:\/\/doi.org\/10.1097\/HEP.0000000000000783.","journal-title":"Hepatology"},{"key":"970_CR43","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1093\/jnci\/64.6.1329","volume":"64","author":"PJ Johnson","year":"1980","unstructured":"Johnson PJ, Williams R. Serum alpha-fetoprotein estimations and doubling time in hepatocellular carcinoma: influence of therapy and possible value in early detection. J Natl Cancer Inst. 1980;64:1329\u201332. https:\/\/doi.org\/10.1093\/jnci\/64.6.1329.","journal-title":"J Natl Cancer Inst"},{"key":"970_CR44","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/s0016-5085(03)00689-9","volume":"125","author":"M Capurro","year":"2003","unstructured":"Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003;125:89\u201397. https:\/\/doi.org\/10.1016\/s0016-5085(03)00689-9.","journal-title":"Gastroenterology"},{"key":"970_CR45","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2165\/00003495-200868020-00007","volume":"68","author":"D Simpson","year":"2008","unstructured":"Simpson D, Keating GM. Sorafenib: in hepatocellular carcinoma. Drugs. 2008;68:251\u20138. https:\/\/doi.org\/10.2165\/00003495-200868020-00007.","journal-title":"Drugs"},{"key":"970_CR46","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723\u201350. https:\/\/doi.org\/10.1002\/hep.29913.","journal-title":"Hepatology"},{"key":"970_CR47","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450\u201361. https:\/\/doi.org\/10.1016\/j.ccell.2015.03.001.","journal-title":"Cancer Cell"},{"key":"970_CR48","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19:151\u201372. https:\/\/doi.org\/10.1038\/s41571-021-00573-2.","journal-title":"Nat Rev Clin Oncol"},{"key":"970_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01549-2","volume":"17","author":"KY Shen","year":"2024","unstructured":"Shen KY, Zhu Y, Xie SZ, Qin LX. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives. J Hematol Oncol. 2024;17:25. https:\/\/doi.org\/10.1186\/s13045-024-01549-2.","journal-title":"J Hematol Oncol"},{"key":"970_CR50","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.immuni.2016.07.009","volume":"45","author":"NE Scharping","year":"2016","unstructured":"Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, Watkins SC, et al. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity. 2016;45:374\u201388. https:\/\/doi.org\/10.1016\/j.immuni.2016.07.009.","journal-title":"Immunity"},{"key":"970_CR51","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s42255-020-00280-9","volume":"2","author":"F Franco","year":"2020","unstructured":"Franco F, Jaccard A, Romero P, Yu YR, Ho PC. Metabolic and epigenetic regulation of T-cell exhaustion. Nat Metab. 2020;2:1001\u201312. https:\/\/doi.org\/10.1038\/s42255-020-00280-9.","journal-title":"Nat Metab"},{"key":"970_CR52","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"CH Chang","year":"2015","unstructured":"Chang CH, Qiu J, O\u2019Sullivan D, Buck MD, Noguchi T, Curtis JD, Chen Q, Gindin M, Gubin MM, van der Windt GJ, Tonc E, Schreiber RD, Pearce EJ, Pearce EL. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162:1229\u201341. https:\/\/doi.org\/10.1016\/j.cell.2015.08.016.","journal-title":"Cell"},{"key":"970_CR53","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013.","journal-title":"Cell"},{"key":"970_CR54","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","volume":"26","author":"PJ Roberts","year":"2007","unstructured":"Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291\u2013310. https:\/\/doi.org\/10.1038\/sj.onc.1210422.","journal-title":"Oncogene"},{"key":"970_CR55","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","volume":"1773","author":"JA McCubrey","year":"2007","unstructured":"McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, et al. Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773:1263\u201384. https:\/\/doi.org\/10.1016\/j.bbamcr.2006.10.001.","journal-title":"Biochim Biophys Acta"},{"key":"970_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-025-03531-3","volume":"44","author":"J Liu","year":"2025","unstructured":"Liu J, Jiang J, Huang J, Fang ZE, Liu L, Liu Y, et al. Bufalin inhibits hepatocellular carcinoma progression by blocking EGFR-mediated RAS-RAF-MEK-ERK pathway activation. J Exp Clin Cancer Res. 2025;44:260. https:\/\/doi.org\/10.1186\/s13046-025-03531-3.","journal-title":"J Exp Clin Cancer Res"},{"key":"970_CR57","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.7150\/ijbs.69969","volume":"18","author":"S Huang","year":"2022","unstructured":"Huang S, Ma Z, Zhou Q, Wang A, Gong Y, Li Z, et al. Genome-wide CRISPR\/Cas9 library screening identified that DUSP4 deficiency induces lenvatinib resistance in hepatocellular carcinoma. Int J Biol Sci. 2022;18:4357\u201371. https:\/\/doi.org\/10.7150\/ijbs.69969.","journal-title":"Int J Biol Sci"},{"key":"970_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13123026","author":"H Moon","year":"2021","unstructured":"Moon H, Ro SW. MAPK\/ERK signaling pathway in hepatocellular carcinoma. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13123026.","journal-title":"Cancers (Basel)"},{"key":"970_CR59","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1172\/JCI63455","volume":"122","author":"WC Tsai","year":"2012","unstructured":"Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest. 2012;122:2884\u201397. https:\/\/doi.org\/10.1172\/JCI63455.","journal-title":"J Clin Invest"},{"key":"970_CR60","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1002\/hep.23875","volume":"52","author":"C Zeng","year":"2010","unstructured":"Zeng C, Wang R, Li D, Lin XJ, Wei QK, Yuan Y, et al. A novel GSK-3 beta\u2013C\/EBP alpha\u2013miR-122\u2013insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma. Hepatology. 2010;52:1702\u201312. https:\/\/doi.org\/10.1002\/hep.23875.","journal-title":"Hepatology"},{"key":"970_CR61","doi-asserted-by":"publisher","DOI":"10.1007\/s10142-024-01403-1","volume":"24","author":"X Yang","year":"2024","unstructured":"Yang X, Xu C, Liu C, Wu X, Chen X, Hou J, et al. TGF-\u03b21-induced LINC01094 promotes epithelial-mesenchymal transition in hepatocellular carcinoma through the miR-122-5p\/TGFBR2\u2013SAMD2\u2013SMAD3 axis. Funct Integr Genomics. 2024;24:123. https:\/\/doi.org\/10.1007\/s10142-024-01403-1.","journal-title":"Funct Integr Genomics"},{"key":"970_CR62","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.mam.2012.07.009","volume":"34","author":"SL Alper","year":"2013","unstructured":"Alper SL, Sharma AK. The SLC26 gene family of anion transporters and channels. Mol Aspects Med. 2013;34:494\u2013515. https:\/\/doi.org\/10.1016\/j.mam.2012.07.009.","journal-title":"Mol Aspects Med"}],"container-title":["Human Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40246-026-00970-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40246-026-00970-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40246-026-00970-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:02:46Z","timestamp":1781827366000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40246-026-00970-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["970"],"URL":"https:\/\/doi.org\/10.1186\/s40246-026-00970-7","relation":{},"ISSN":["1479-7364"],"issn-type":[{"value":"1479-7364","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal study was performed following the Guide for the Care and Use of Laboratory Animals published by the NIH and adhered to the 3Rs principles. The experimental protocol was approved by the Experimental Animal Welfare and Ethics Committee of the Second Clinical Medical College of Lanzhou University (Approval No. D2024-858).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors reviewed and approved the final version of the manuscript and agreed to its publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"100"}}